<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6739">
  <stage>Registered</stage>
  <submitdate>16/12/2016</submitdate>
  <approvaldate>16/12/2016</approvaldate>
  <nctid>NCT03003533</nctid>
  <trial_identification>
    <studytitle>A Gene Transfer Study for Hemophilia A</studytitle>
    <scientifictitle>Gene Transfer, Dose-Finding Safety, Tolerability, and Efficacy Study of SPK-8011 [a Recombinant Adeno-Associated Viral Vector With Human Factor VIII Gene] in Individuals With Hemophilia A</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>SPK-8011-101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hemophilia A</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - SPK-8011

Experimental: SPK-8011 - All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.


Other interventions: SPK-8011
A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of study-related adverse events, including clinically significant abnormal laboratory values - adverse events</outcome>
      <timepoint>52 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Changes from baseline in FVIII activity levels after a single outpatient administration of SPK-8011 - changes in FVIII activity levels</outcome>
      <timepoint>52 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Kinetic assessment of SPK-8011 including shedding of vector DNA in bodily fluids - vector shedding</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of participants requiring a course of steroid therapy for the elevations in liver enzymes - number of participants requiring steroids</outcome>
      <timepoint>52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males age18 years or older

          -  Confirmed diagnosis of hemophilia A as evidenced by their medical history with plasma
             FVIII activity levels = 2% of normal

          -  Have received &gt;150 exposure days (EDs) to FVIII concentrates or cryoprecipitate

          -  Have experienced &gt;10 bleeding events over the previous 12 months only if receiving
             on-demand therapy and having FVIII baseline level 1-2% of normal

          -  Have no prior history of allergic reaction to any FVIII product

          -  Have no measurable inhibitor against factor VIII inhibitor as assessed by the central
             laboratory and have no prior history of inhibitors to FVIII protein

          -  Agree to use reliable barrier contraception</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Evidence of active hepatitis B or C

          -  Currently on antiviral therapy for hepatitis B or C

          -  Have significant underlying liver disease

          -  Have serological evidence* of HIV-1 or HIV-2 with CD4 counts =200/mm3 (* participants
             who are HIV+ and stable with CD4 count &gt;200/mm3 and undetectable viral load are
             eligible to enroll)

          -  Have detectable antibodies reactive with AAV-Spark200 capsid

          -  Participated in a gene transfer trial within the last 52 weeks or in a clinical trial
             with an investigational product within the last 12 weeks</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hosptial - Camperdown</hospital>
    <postcode>2050 - Camperdown</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Spark Therapeutics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the
      safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals
      with hemophilia A.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03003533</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Director</name>
      <address>Spark Therapeutics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Clinical Director</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@sparktx.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>